Trial · NCT02154529
Results by group35
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 35
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Safety and Tolerability: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) by Severity and/or Relationship to Tesevatinib | Arm 1: Tesevatinib 150 mg PO QD + Trastuzumab 8 mg/kg IV | Grade ≥ 3 | 1 | Participants | |
| Safety and Tolerability: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) by Severity and/or Relationship to Tesevatinib | Arm 2: Tesevatinib 250 mg PO QD + Trastuzumab 8 mg/kg IV | Grade ≥ 3 | 1 | Participants | |
| Safety and Tolerability: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) by Severity and/or Relationship to Tesevatinib | Arm 3: Tesevatinib 300 mg PO QD + Trastuzumab 8 mg/kg IV | Grade ≥ 3 | 5 | Participants | |
| Safety and Tolerability: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) by Severity and/or Relationship to Tesevatinib | Arm 4: Tesevatinib 350 mg PO QD + Trastuzumab 8 mg/kg IV | Grade ≥ 3 | 2 | Participants | |
| Safety and Tolerability: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) by Severity and/or Relationship to Tesevatinib | All Patients | Grade ≥ 3 | 9 | Participants | |
| Safety and Tolerability: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) by Severity and/or Relationship to Tesevatinib | Arm 1: Tesevatinib 150 mg PO QD + Trastuzumab 8 mg/kg IV | Related to Tesevatinib | 4 | Participants | |
| Safety and Tolerability: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) by Severity and/or Relationship to Tesevatinib | Arm 2: Tesevatinib 250 mg PO QD + Trastuzumab 8 mg/kg IV | Related to Tesevatinib | 3 | Participants | |
| Safety and Tolerability: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) by Severity and/or Relationship to Tesevatinib | Arm 3: Tesevatinib 300 mg PO QD + Trastuzumab 8 mg/kg IV | Related to Tesevatinib | 7 | Participants | |
| Safety and Tolerability: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) by Severity and/or Relationship to Tesevatinib | Arm 4: Tesevatinib 350 mg PO QD + Trastuzumab 8 mg/kg IV | Related to Tesevatinib | 2 | Participants | |
| Safety and Tolerability: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) by Severity and/or Relationship to Tesevatinib | All Patients | Related to Tesevatinib | 16 | Participants | |
| Safety and Tolerability: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) by Severity and/or Relationship to Tesevatinib | Arm 1: Tesevatinib 150 mg PO QD + Trastuzumab 8 mg/kg IV | Grade ≥ 3 Related to Tesevatinib | 1 | Participants | |
| Safety and Tolerability: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) by Severity and/or Relationship to Tesevatinib | Arm 2: Tesevatinib 250 mg PO QD + Trastuzumab 8 mg/kg IV | Grade ≥ 3 Related to Tesevatinib | 1 | Participants | |
| Safety and Tolerability: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) by Severity and/or Relationship to Tesevatinib | Arm 3: Tesevatinib 300 mg PO QD + Trastuzumab 8 mg/kg IV | Grade ≥ 3 Related to Tesevatinib | 2 | Participants | |
| Safety and Tolerability: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) by Severity and/or Relationship to Tesevatinib | Arm 4: Tesevatinib 350 mg PO QD + Trastuzumab 8 mg/kg IV | Grade ≥ 3 Related to Tesevatinib | 2 | Participants | |
| Safety and Tolerability: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) by Severity and/or Relationship to Tesevatinib | All Patients | Grade ≥ 3 Related to Tesevatinib | 6 | Participants | |
| Safety and Tolerability: Percentage of Subjects With Serious Adverse Event (SAE) Related to Tesevatinib | Arm 1: Tesevatinib 150 mg PO QD + Trastuzumab 8 mg/kg IV | 0 | Participants | ||
| Safety and Tolerability: Percentage of Subjects With Serious Adverse Event (SAE) Related to Tesevatinib | Arm 2: Tesevatinib 250 mg PO QD + Trastuzumab 8 mg/kg IV | 1 | Participants | ||
| Safety and Tolerability: Percentage of Subjects With Serious Adverse Event (SAE) Related to Tesevatinib | Arm 3: Tesevatinib 300 mg PO QD + Trastuzumab 8 mg/kg IV | 2 | Participants | ||
| Safety and Tolerability: Percentage of Subjects With Serious Adverse Event (SAE) Related to Tesevatinib | Arm 4: Tesevatinib 350 mg PO QD + Trastuzumab 8 mg/kg IV | 1 | Participants | ||
| Safety and Tolerability: Percentage of Subjects With Serious Adverse Event (SAE) Related to Tesevatinib | All Patients | 4 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02154529/results